<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496897</url>
  </required_header>
  <id_info>
    <org_study_id>FP02.2_CS_01</org_study_id>
    <nct_id>NCT02496897</nct_id>
  </id_info>
  <brief_title>Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B&#xD;
      vaccine, administered as an add-on therapy to entecavir or tenofovir.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B&#xD;
      vaccine, administered as an add-on therapy to entecavir or tenofovir. HBeAg-negative subjects&#xD;
      will be randomized to receive low or high dose vaccine, in the presence or absence of IC31®&#xD;
      adjuvant, or to receive placebo or IC31® adjuvant alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">June 5, 2018</completion_date>
  <primary_completion_date type="Actual">October 13, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Adverse Events and Clinical Laboratory Abnormalities</measure>
    <time_frame>Throughout the study to day 85</time_frame>
    <description>Adverse Events and Clinical Laboratory Abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>Throughout the study to day 85</time_frame>
    <description>IFN-gamma ELISpot assay specific for FP-02.2 peptides using cryopreserved PBMCs</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>FP-02.2 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of the FP-02.2 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-02.2 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of the FP-02.2 vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-02.2 Low Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose of the FP-02.2 vaccine with IC31® Adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-02.2 High Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A high dose of the FP-02.2 vaccine with IC31® Adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo component.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC31® Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC31® Adjuvant alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FP-02.2 Vaccine</intervention_name>
    <description>Synthetic Peptide Hepatitis B Vaccine</description>
    <arm_group_label>FP-02.2 High Dose</arm_group_label>
    <arm_group_label>FP-02.2 High Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_label>FP-02.2 Low Dose</arm_group_label>
    <arm_group_label>FP-02.2 Low Dose with IC31® Adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IC31® Adjuvant</intervention_name>
    <description>IC31® Adjuvant</description>
    <arm_group_label>FP-02.2 High Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_label>FP-02.2 Low Dose with IC31® Adjuvant</arm_group_label>
    <arm_group_label>IC31® Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects aged 18-65 years.&#xD;
&#xD;
          2. Diagnosed with chronic hepatitis B defined as HBsAg positive for at least 24 months.&#xD;
&#xD;
          3. Subject has received entecavir or tenofovir for at least 2 years with a stable dose&#xD;
             for at least 6 months prior to screening.&#xD;
&#xD;
          4. HBeAg negative for at least 2 years prior to inclusion in the study.&#xD;
&#xD;
          5. HBV DNA &lt;50 IU/mL for ≥ 12 months&#xD;
&#xD;
          6. ALT/AST ≤ 1.5 x ULN via the local laboratory at the Screening Visit&#xD;
&#xD;
          7. Able to give written informed consent to participate&#xD;
&#xD;
          8. Females should fulfil one of the following criteria:&#xD;
&#xD;
               1. At least one year menopausal&#xD;
&#xD;
               2. Surgically sterile&#xD;
&#xD;
               3. Same-sex relationship&#xD;
&#xD;
               4. WOCBP not surgically sterilized or with laboratory confirmed menopausal status&#xD;
                  are required to use a highly effective contraceptive measure with low used&#xD;
                  dependency from screening until one menstrual cycle after the last dose of IMP&#xD;
                  (Day 58) such as:&#xD;
&#xD;
                    -  Combined (oestrogen- and progestogen-containing) hormonal contraception&#xD;
                       associated with inhibition of ovulation&#xD;
&#xD;
                    -  Progestogen-only hormonal contraception implants associated with inhibition&#xD;
                       of ovulation&#xD;
&#xD;
                    -  Intrauterine device (IUD)&#xD;
&#xD;
                    -  Intrauterine hormone-releasing system (IUS)&#xD;
&#xD;
                    -  Bilateral tubal occlusion&#xD;
&#xD;
                    -  Vasectomised partner - must have had medical assessment of successful&#xD;
                       surgery.&#xD;
&#xD;
        From screening until one menstral cycle after the last dose of IMP (day 57).&#xD;
&#xD;
        Subjects who practice true abstinence or who exclusively have same sex partners need not&#xD;
        use contraception, provided it is in line with their preferred and usual lifestyle.&#xD;
        Periodic abstinence (eg calendar, ovulation, symptothermal, post-ovulation methods) and&#xD;
        withdrawal are not acceptable methods of contraception. Should any such subject stop&#xD;
        practicing true abstinence, they must use contraception as described above.&#xD;
&#xD;
        Males should fulfil one of the following criteria:&#xD;
&#xD;
          -  Surgically sterile&#xD;
&#xD;
          -  Willing to abstain from sexual intercourse or use a reliable form of contraception&#xD;
             (e.g. condom), if having sex with a pregnant or non-pregnant woman of childbearing&#xD;
             potential, from screening until 3 months after the final dose of IMP.&#xD;
&#xD;
          -  Surgically sterilised or post-menopausal female partner or same-sex relationship.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Liver disease other than chronic hepatitis B (a diagnosis of steatosis is permitted&#xD;
             providing inclusion criterion 6 is met).&#xD;
&#xD;
          2. Evidence of Liver cirrhosis on Fibroscan screening (Liver cirrhosis is defined as a&#xD;
             Fibroscan measurement of &gt;11.5 KPa), or previous history or evidence of cirrhosis on&#xD;
             radiological imaging, Fibroscan or liver biopsy.&#xD;
&#xD;
          3. Positive serology for HIV-1 or HIV-2 or HCV or HDV antibodies.&#xD;
&#xD;
          4. Immunodeficient or autoimmune conditions due to disease or medication e.g. systemic&#xD;
             steroids within previous 12 weeks. (Topical or inhaled steroids are permissible).&#xD;
&#xD;
          5. Clinically relevant co-morbidity, e.g. autoimmune disease.&#xD;
&#xD;
          6. Clinically relevant anaemia or leukopenia in the opinion of the investigator.&#xD;
&#xD;
          7. Cancer or treatment for cancer within 3 years prior to screening excluding basal cell&#xD;
             carcinoma of the skin, which is allowed.&#xD;
&#xD;
          8. Known or suspected intolerance or hypersensitivity to the IMP or closely related&#xD;
             compounds or any of the stated ingredients.&#xD;
&#xD;
          9. Receipt of any IMP within 90 days prior to screening or currently receiving IMP or&#xD;
             intent to receive IMP.&#xD;
&#xD;
         10. Current substance or alcohol abuse that in the opinion of the Investigator would&#xD;
             interfere with compliance or with interpretation of study results.&#xD;
&#xD;
         11. Any condition that in the opinion of the Investigator might interfere with study&#xD;
             objectives.&#xD;
&#xD;
         12. Pregnant or breastfeeding.&#xD;
&#xD;
         13. Subjects should not have received, during the 6 month period prior to screening, any&#xD;
             medications or other treatments that may adversely affect the immune system such as&#xD;
             allergy injections, immunoglobulins, interferons, cytotoxic drugs or other drugs known&#xD;
             to be frequently associated with significant major organ toxicity, or systemic&#xD;
             corticosteroids (oral or injectable).&#xD;
&#xD;
             Immunosuppressive treatment such as azathioprine or mercaptopurine is not permitted 6&#xD;
             months prior to screening.&#xD;
&#xD;
         14. Administration of live vaccines (such as live influenza vaccinations or live travel&#xD;
             vaccinations) from 10 days prior to the screening visit until Day 85.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Thursz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Busan Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and The London School of Medicine and Dentistry, Blizzard Institiue</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital and Medical School</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London - St Mary's Campus</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennine Acute Hospitals</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals, Bradford Royal Infirmary</name>
      <address>
        <city>North Yorkshire</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre, Nottingham Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 12, 2019</submitted>
    <submission_canceled>March 14, 2019</submission_canceled>
    <submitted>March 14, 2019</submitted>
    <returned>June 14, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

